Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.
Klaus Peter DieckmannTomas PokrivcakLajos GecziDavid NiehausInken Dralle-FilizCord MatthiesTamas DienesStefanie ZschäbitzPia PaffenholzTanja GschliesserRenate PichlerMichal MegoPia BaderFriedemann ZengerlingJulia HeinzelbeckerPhilipp KrausewitzSusanne KregeGaetano AurilioCem AksoyMarcus HentrichChristoph SeidelPéter TörzsökTim NestlerMatthaeus MajewskiAndreas HiesterTomas BuchlerSonia ValletHana StudentovaSandra SchönburgDora Niedersüß-BekeJulia RingEmanuela TrentiAxel HeidenreichChristian WülfingHendrik IsbarnUwe PichlmeierMartin PichlerPublished in: Therapeutic advances in medical oncology (2022)
The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.